Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) bronchodilator. It is a muscarinic M3, M2 antagonist with a long residence time at M3 receptors and a shorter residence time at M2 receptors. Aclidinium bromide was approved for the treatment of chronic obstructive pulmonary disease (COPD) in July 2012.
The Journal of pharmacology and experimental therapeutics, 331(2), 740-751 (2009-08-28)
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M(1)-M(5)). [(3)H]Aclidinium dissociated slightly faster from M(2) and M(3) receptors
Therapeutic advances in respiratory disease, 6(6), 345-361 (2012-10-19)
Long-acting muscarinic antagonists (LAMAs) play a central role in the management of chronic obstructive pulmonary disease (COPD). Previously, only one LAMA (tiotropium) was available for the treatment of COPD, necessitating the development of other therapeutic options due to the heterogeneity
European review for medical and pharmacological sciences, 23(1), 105-112 (2019-01-19)
Osteosarcoma is recognized as the most common primary malignant bone tumor, the 5-year disease-free survival rate in patients with metastatic or recurrent disease is below than 30%. Drug resistance and toxic side effects limit the therapeutic efficacy of osteosarcoma. Therefore
